Literature DB >> 32592470

Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib.

Joy A Lee1, Pooja R Magavi1, Gauree G Konijeti2.   

Abstract

Entities:  

Year:  2020        PMID： 32592470     DOI： 10.1093/ibd/izaa158

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  2 in total

1.  Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.

Authors:  Quazim A Alayo; Aava Khatiwada; Anish Patel; Maria Zulfiqar; Anas Gremida; Alexandra Gutierrez; Richard P Rood; Matthew A Ciorba; George Christophi; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 7.290

Review 2.  Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.

Authors:  Nikoleta Zioga; Dionysios Kogias; Vasiliki Lampropoulou; Nikolaos Kafalis; Charalampos Papagoras
Journal:  Mediterr J Rheumatol       Date:  2022-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.